NovoCure Ltd — Form 8-K
Filed October 29, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
NovoCure reported Q3 2026 net revenue of $193.4M (16% YoY growth) driven by 19% active patient growth to 5,260 globally. The company raised full-year 2026 guidance to $736M–$743M revenue (prior: $710M–$725M) and $24M–$34M adjusted EBITDA (prior: $0M–$15M). Key driver: Optune Gio remains core (4,729 patients); newer products Optune Lua (255 patients, +83% YoY) and Optune Pax (276 patients, newly launched) contributed $11.9M combined quarterly revenue. Japan approved Optune Pax in October 2026. Adjusted EBITDA swung to $15.7M positive (Q3 2025: -$3.0M). However, net loss was $10.4M (Q3 2025: -$37.3M loss), and company remains unprofitable YTD.
Why this rating
Guidance raise and margin expansion are meaningful for a $995M-cap company. Revenue trajectory and path toward profitability material; new market approvals and product mix diversification reduce reliance on single product.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.